A Phase 1 Study to Evaluate Safety and Tolerability of NKTR-214 (BMS-986321) Administered in Combination With Nivolumab (BMS-936558) in Advanced Malignant Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 17 Jun 2019 Status changed from not yet recruiting to recruiting.
- 31 Jan 2019 Planned initiation date changed from 25 Jan 2019 to 8 Feb 2019.
- 07 Jan 2019 Planned initiation date changed from 25 Jan 2018 to 25 Jan 2019.